Should biologics for psoriasis be interrupted in the era of COVID-19?
Mark Lebwohl, Ryan Rivera‐Oyola, Dédée F. Murrell
Topics & Concepts
MedicinePsoriasisPlaceboClinical trialCoronavirus disease 2019 (COVID-19)Internal medicineHydroxychloroquinePandemicImmunologyInfectious disease (medical specialty)DiseaseAlternative medicinePathologyPsoriasis: Treatment and PathogenesisAutoimmune and Inflammatory Disorders ResearchDermatology and Skin Diseases